TABLE 3.
Sorafenib dose reduction and discontinuation according to dose group
|
Sorafenib dose/day
|
P | ||
|---|---|---|---|
| 800 mg (n=33) | 400 mg (n=66) | ||
| Dose reduction | 22 (66) | 26 (40) | 0.018 |
| Time to dose reduction, months, median (range) | 1.4 (0.3–8.4) | N/A | |
| Duration of treatment, months, mean | 6 | 5.4 | |
| Discontinuation | 28 (85) | 46 (70) | 0.14 |
| Reason for discontinuation | |||
| Adverse effect | 9 (27) | 22 (33) | 0.65 |
| Disease progression | 14 (43) | 19 (29) | 0.18 |
| Other/unknown | 5 (15) | 5 (8) | 0.29 |
Data presented as n (%) unless otherwise indicated. Bolded value indicates statistical significance. N/A Not applicable